论文部分内容阅读
目的探讨黛力新与思连康联合美沙拉秦治疗肠易激综合征患者的临床疗效。方法严格按照病例的纳入和排除标准,选取2014年3月—2016年3月在华北理工大学附属医院消化内科住院的肠易激综合征患者126例,将所有患者随机分为A组、B组、C组,每组42例,A组给予黛力新治疗,B组给予黛力新+思连康治疗,C组给予黛力新+思连康+美沙拉秦治疗;治疗2~3周后,观察三组患者腹痛、腹胀、便秘、腹泻、精神焦虑等临床症状改善情况,比较三组患者治疗效果。结果 1A组患者的有效率为76.2%,B组的有效率为88.1%,C组的有效率为95.2%,明显高于A、B二组,差异具有统计学意义(P<0.05);2B组与C组各项指标疗效改善情况优于A组,差异具有统计学意义(P<0.05),尤其以C组症状改善最明显,差异具有统计学意义(P<0.01)。结论黛力新与思连康联合美沙拉秦治疗肠易激综合征患者具有协同作用,能够明显改善患者的临床不适症状,具有良好的治疗效果。
Objective To investigate the clinical effect of Deanxit and silcon combination with mesalazine in the treatment of patients with irritable bowel syndrome. Methods In strict accordance with the inclusion and exclusion criteria of cases, 126 patients with IBS admitted in Department of Gastroenterology, Affiliated Hospital of North China University of Science and Technology from March 2014 to March 2016 were selected and all patients were randomly divided into A group, B group , C group, 42 cases in each group, A group was given Deanxit treatment, B group was given Deanxit + Si Liankang treatment, C group was given Deanxit + Si Liankang + Mesalazine treatment; treatment of 2 to 3 weeks After three groups of patients were observed abdominal pain, abdominal distension, constipation, diarrhea, mental anxiety and other clinical symptoms to improve the treatment of patients compared three groups. Results The effective rate of group A was 76.2%, that of group B 88.1%, group C 95.2%, significantly higher than group A and group B (P <0.05); 2B Group C and C indicators improved the efficacy of better than the A group, the difference was statistically significant (P <0.05), especially in group C the most obvious improvement in symptoms, the difference was statistically significant (P <0.01). Conclusion Deanxit and Silicone combined with Mesalazine have synergistic effects in the treatment of patients with irritable bowel syndrome, and can significantly improve the clinical symptoms of patients with good therapeutic effect.